Literature DB >> 3976787

Oxytocin augmentation of dysfunctional labor. V. An alternative oxytocin regimen.

J Seitchik, J A Amico, M Castillo.   

Abstract

A regimen is described in which the time from the start of a large dose of oxytocin to a myometrial response was used for selection of a maintenance dose. The method is based on our experience that continuous intravenous doses of oxytocin in the therapeutic range for the augmentation of labor require about 40 minutes of intravenous infusion to achieve a steady-state plasma concentration of oxytocin. The method effectively identified the proper maintenance dose on the first attempt in 43 of 59 patients (73%) and on the second in 58 of 59. The doses selected effected cervical dilatation in 55 of 59 cases (93%). Comparison of the timed dose method with an arithmetic progression regimen revealed the former method to select the minimum effective dose more rapidly, but that method had no advantage in shortening the time from the start of oxytocin to complete cervical dilatation. Examination of the plasma concentration of oxytocin by radioimmunoassay demonstrates that the maintenance dose selected by the duration of the interval from the start of infusion to a myometrial response sustains the plasma oxytocin concentration obtained by the initial dose. These data lend additional evidence that any particular dose of oxytocin in the therapeutic range requires approximately 40 minutes to achieve a steady-state plasma concentration.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3976787     DOI: 10.1016/0002-9378(85)90514-9

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  2 in total

1.  Oxytocin and the augmentation of labor : Human and medical perspectives.

Authors:  P Curtis
Journal:  Hum Nat       Date:  1993-12

2.  Two-step inhibitory effect of kanzo on oxytocin-induced and prostaglandin F2α-induced uterine myometrial contractions.

Authors:  Genichiro Sumi; Katsuhiko Yasuda; Chiharu Kanamori; Megumi Kajimoto; Akemi Nishigaki; Tomoko Tsuzuki; Hisayuu Cho; Hidetaka Okada; Hideharu Kanzaki
Journal:  J Nat Med       Date:  2014-04-17       Impact factor: 2.343

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.